PG203 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease1

6. Parkinson disease


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-006004-16-PL
(EUCTR)
16/07/202123/04/2021Phase II clinical trial to assess anti-dyskinetic efficacy of CPL500036, in patients with levodopa-induced dyskinesia in Parkinson's diseasePhase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Disease Suffering from Levodopa Induced Dyskinesia Levodopa-induced dyskinesia in Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Code: PG203
INN or Proposed INN: CPL500036
Other descriptive name: CPL500036
Celon Pharma S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
108Phase 2Poland